44 results about "Disease activity" patented technology

The application discloses an application of Bacteroides intestinalis in preventing and / or treating ulcerative colitis and belongs to the field of biopharmacy. The application claims the use of Bacteroides intestinalis in preparing a medicine or a composition for preventing and / or treating ulcerative colitis. It is found that Bacteroides intestinalis can significantly inhibit the weight loss of a mouse model of ulcerative colitis, reduce a disease activity index, repair colon tissue damage, and down-regulate the expression level of a proinflammatory factor of the organism, and thus has a clear preventive and / or therapeutic effect on ulcerative colitis and has a good clinical transformation application prospect. Therefore, the Bacteroides intestinalis has a prospect of being developed into a medicine or a composition for preventing and / or treating ulcerative colitis.

This application discloses the application of dasabuvir as a TRPV4 inhibitor in improving diseases caused by increased TRPV4 expression or enhanced activity, particularly ulcerative colitis. Specifically, it relates to the biomedical field. Dasabuvir is a novel TRPV4 inhibitor that can improve symptoms in a DSS-induced mouse ulcerative colitis model and is suitable for use in TRPV4 inhibitor drugs and ulcerative colitis drugs. In HEK-293 cells overexpressing TRPV4, dasabuvir can dose-dependently inhibit the increase in intracellular calcium ion concentration induced by the TRPV4-specific agonist GSK1016790A within a concentration range of 0.03-30 μM, with an IC50 concentration of [missing information]. 50 At a concentration of 0.27 μM, Dasabuvir is a highly active TRPV4 inhibitor. In a DSS-induced ulcerative colitis model, Dasabuvir can improve weight loss, reduce the disease activity index, alleviate colonic shortening, reduce histopathological changes, and inhibit the expression of inflammatory factors, thus improving ulcerative colitis.

The application relates to application of a reagent for detecting expression levels of a PSIP1 gene or a coded protein LEDGF / p75 in preparation of a product for evaluating systemic lupus erythematosus disease activity, which makes up for the problems of insufficient sensitivity and specificity of existing evaluation indexes; the application also discloses a key role of the PSIP1 gene in a pathogenesis mechanism of systemic lupus erythematosus, and clearly shows the relationship between the PSIP1 gene in T cells and cell cycle arrest, cell aging and abnormal immune function, so as to provide a theoretical basis for target regulation of the PSIP1 to improve T cell function and delay or block disease progression; the application firstly proposes that the expression levels of the PSIP1 / LEDGF / p75 are detected to be used for evaluating systemic lupus erythematosus disease activity, auxiliary diagnosis, prognosis prediction and treatment effect monitoring, so as to provide a brand-new tool and direction for precise diagnosis, activity evaluation, prognosis judgment and future target treatment development of systemic lupus erythematosus.

The present application relates to a new use of halogenophenol compound 4,5,2'-trihydroxy-2,5'-dibromobenzophenone, in particular in the preparation of a drug for treating inflammatory bowel disease. The halogenophenol compound of the present application can significantly alleviate the weight loss and colon shortening of the colonitis model, reduce the disease activity index of the colonitis model, reduce the inflammatory cell infiltration of the colonitis model, reduce the expression of inflammatory factors, has an immune regulation function on the intestinal tract, and is superior to the clinical first-line drug mesalazine in most indicators, and has application prospects in the treatment of inflammatory bowel disease.

A method to assess the disease status, determine the mean / average control of the disease and monitor the compliance to treatment over a period of time of a respiratory disease, comprising of predicting the degree of airway inflammation and disease activity by measuring the inflammatory markers, evaluating the mucosal integrity / damage by measuring the moisture levels of the exhaled air, evaluating the breathing function and obstruction by measuring the FEV1 value, and evaluating the symptom control by determining the COPD Score.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of ethyl acetate extract of turmeric in the preparation of drugs for treating colorectal cancer. The preparation method of the extract is as follows: turmeric slices are soaked overnight in 15 times their weight of a 70% (v / v) ethanol solution, refluxed at 85°C three times, 2 hours each time. The extracts are combined and concentrated until no alcohol odor remains. The extract is then dried to constant weight to obtain the total extract. The total extract is reconstituted with water and extracted three times with ethyl acetate at an equal volume ratio. The extracts are combined and dried to constant weight to obtain the final product. Experimental results show that this extract is particularly effective in improving disease activity index, restoring colon length, reducing tumor number, and alleviating histopathological damage, and has no significant toxicity to major organs. This extract can be formulated into oral or injectable preparations, providing a new natural drug candidate for the treatment of colorectal cancer.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The application belongs to the technical field of microorganisms, and discloses Lactobacillus fermentum (L.f) LFSJ001 and application thereof in preparation of products for preventing or treating ulcerative colitis. The Lactobacillus fermentum LFSJ001 is independently isolated and identified. It is found through the use of DSS to construct a mouse colitis model that the Lactobacillus fermentum LFSJ001 combined with 5-Aminosalicylic Acid (5-ASA) can enhance the improvement of 5-ASA on the symptoms of colitis, including multiple indexes such as disease activity index, colon injury, and spleen index. It can be seen that the Lactobacillus fermentum LFSJ001 can be used as a combined drug of 5-ASA, enhance the efficacy of 5-ASA, inhibit the occurrence and development of ulcerative colitis, and improve the intestinal barrier. The application provides a new diagnosis and treatment direction and strategy for the prevention and treatment of ulcerative colitis.

Methods for characterizing disease activity in a systemic lupus erythematosus (SLE) patient. Methods include obtaining a blood, serum, plasma, or urine sample from the patient; assessing the sample for expression of a biomarker selected from the group consisting of IFN-α, IL-10, BLyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4; assessing the sample for expression of an inflammatory mediator selected from the group consisting of TNFRII, Resistin, and Osteopontin (OPN); assessing the sample for an SLE-associated autoantibody specificity biomarker selected from the group consisting of dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP; and calculating a Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score may distinguish between active and low lupus disease activity. Methods of treatment are also provided including administering a treatment prior to reaching clinical disease classification after determining that the patient has the prognosis for transitioning to classified SLE.

The present application relates to the technical field of rheumatism and immunity disease management, and particularly relates to a remote intelligent management method and system for rheumatism and immunity patients. Clinical indexes, environmental monitoring and life behavior data are acquired to construct a multi-element characteristic vector, which is input into a deep learning network to obtain a disease activity prediction result; the prediction result and the characteristic vector are input into a recurrence risk assessment network containing a collaborative constraint layer, and a consistency correction is performed based on a medical prior constraint to obtain a risk assessment result; a counterfactual replacement is performed on the characteristic vector through a causal inference algorithm, the risk assessment network is input to obtain a counterfactual prediction value, a difference value is calculated as a causal contribution degree, risk driving factors are screened, and quantitative intervention suggestions are generated; and operable early warning information is generated based on the driving factors and the intervention suggestions. The present application improves the accuracy of recurrence risk prediction and the pertinence of intervention suggestions.

The application discloses application of forskolin and / or isoforskolin in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of medicines.The medicine can significantly improve the disease phenotype of colitis, including relieving weight loss, reducing disease activity index score, improving colon length shortening and histopathological damage.The mechanism of action involves multiple targets: repairing intestinal mucosal barrier function, reducing local inflammation of the colon, and regulating intestinal flora balance, restoring the abundance of beneficial bacteria and inhibiting the proliferation of pathogenic bacteria.The application provides a candidate drug with anti-inflammatory, barrier repair and flora regulation functions for the treatment of colitis, and expands the medical use of forskolin or isoforskolin.

The present application discloses diagnostic methods and kits for detecting disease activity in a subject having an inflammatory bowel disease, such as Crohn's disease. Methods of treating endoscopically active gastrointestinal disease, as well as methods of determining effectiveness of a treatment for endoscopically active gastrointestinal disease in a subject, are also disclosed.

The application discloses a prillium fimicola for relieving ulcerative colitis and application thereof, and belongs to the technical field of microorganisms. The prillium fimicola N03 can improve body weight loss and disease activity index increase caused by ulcerative colitis, inhibit colon atrophy, protect the integrity of colon tissue structure, increase the number of goblet cells, reduce the inflammation level in the intestinal tract, can significantly up-regulate the expression of Nrf2 , Gpx2 and Nqo1 in the body of a mouse with colitis, effectively improve the impaired activation of Nrf2 signal pathway in the body of the mouse, and has a good relieving effect on colitis. The prillium fimicola N03 has a very wide application prospect when used for preparing a medicine composition for relieving ulcerative colitis and a fermented food.​​​​​​​​

This invention belongs to the field of bacterial agent preparation and biomedical technology, specifically relating to a strain of *Lactobacillus reuteri*, a bacterial agent, and its application in treating ulcerative colitis. This invention isolated a strain of *Lactobacillus reuteri*, named PFL-2501, and preserved it biologically. The *Lactobacillus reuteri* PFL-2501 exhibits strong gastrointestinal tolerance and high safety, with no hemolytic properties. It can inhibit harmful pathogenic bacteria in the intestine, regulate immune balance, reduce the content of pro-inflammatory factors in colonic tissue, decrease peroxidase activity, increase the level of anti-inflammatory factors, and improve the expression of intestinal tight junction proteins. The results of the examples show that *Lactobacillus reuteri* PFL-2501 and its bacterial agent can reduce weight loss in ulcerative colitis model mice, reduce the disease activity index, prolong colon length, protect the integrity of the colonic mucosa, and reduce inflammatory damage, thereby achieving a significant effect in alleviating ulcerative colitis.

The application discloses a transrectal biplane ultrasonic imaging method for evaluating ulcerative colitis disease activity and a storage medium, and comprises the following steps: S1, probe placement: a biplane ultrasonic probe equipped with two scanning planes, i.e., a linear array and a convex array, is placed into a rectum of a patient through the anus; S2, biplane synchronous imaging and data acquisition: in a target rectal segment, the biplane ultrasonic probe is used to scan in the linear array plane and the convex array plane simultaneously or successively to obtain ultrasonic image data of the target rectal segment in the two mutually perpendicular planes; S3, key index evaluation: based on the biplane ultrasonic image data obtained in step S2, key indexes for reflecting ulcerative colitis inflammation activity are evaluated, and the key indexes comprise intestinal wall thickness and intestinal wall blood flow signals; and S4, comprehensive evaluation: the biplane key indexes evaluated in step S3 are integrated to quantitatively evaluate ulcerative colitis disease activity.

The embodiment of the application discloses a kind of vitiligo auxiliary diagnosis methods, devices and storage medium of multi-modal medical image collaborative segmentation and classification, wherein the method comprises: obtaining the multi-modal image pair of the clinical image and Wood lamp image of the same examinee;According to the imaging characteristics of two kinds of modalities, the image pair is preprocessed and modality-specific data enhancement;The multi-modal image pair after processing is input into the feature extraction network to obtain each modality feature, and spatial guidance information for subsequent segmentation is generated;Each modality feature is input into vector quantization fusion module for cross-modal feature fusion to obtain semantic consistent fusion feature;Based on the fusion feature, a segmentation branch and a classification branch are constructed to realize the joint output of lesion region segmentation and disease activity classification, and the collaborative effect of the two tasks is improved through inter-task interaction. By using the present application, end-to-end joint optimization of vitiligo lesion segmentation and disease activity classification can be realized, and the diagnostic performance is improved.

This invention relates to the application of stem cell exosomes in drugs for treating ulcerative colitis. The stem cell exosomes include antler stem cell-derived exosomes (ASC-exo) and human umbilical cord mesenchymal stem cell-derived exosomes (HucMSC-exo). The drugs used in this invention can promote the proliferation and migration of NCM460 colonic epithelial cells and reduce apoptosis; they can regulate macrophage polarization, shifting it from M1 to M2 polarization; in vivo experiments, they alleviate DSS-induced weight loss, reduced food intake, and shortened colon length in mice, improve disease activity index, and effectively reduce pathological changes observed in ulcerative colitis models, providing new insights for drug development in inflammatory bowel disease.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

This invention relates to a composition for preventing colitis-associated colorectal cancer and controlling weight, comprising seahorse, laver, kelp, spirulina, Ulva procumbens, and Gracilaria in a specific ratio. This formula is based on traditional Chinese medicine theories such as "five colors entering the five internal organs," "five flavors entering the meridians," and "salt can soften hardness," while also considering the combined use of warming and cooling properties, and the integration of clearing and tonifying. Through the combination of various marine algae and seahorse, it achieves synergistic effects on multiple targets, including immune regulation, anti-inflammation, intestinal barrier repair, and weight control. The preparation method is simple and low-cost, suitable for large-scale production in food and dietary supplements. Animal experiments show that this composition can significantly slow weight gain in normal mice. In an AOM / DSS-induced colitis-associated colorectal cancer model, it can reduce the disease activity index, decrease the number of colon tumors, alleviate abnormal organ enlargement and intestinal pathological damage, downregulate inflammatory factors such as iNOS and Cox-2, and upregulate intestinal barrier-related factors such as Cdh1, demonstrating a good preventive intervention effect.

The application discloses a kind of prevention and cure inflammatory bowel disease complex probiotic and its application, belong to biological medicine technical field.The prevention and cure inflammatory bowel disease complex probiotic includes Tianzhong Collins bacteria and three chain type bacillus;Tianzhong Collins bacteria and three chain type bacillus are mixed in proportion;The complex probiotic of the application has excellent performance in resistance and bacteriostasis etc.;Can improve the situation such as mouse weight loss caused by inflammatory bowel disease, disease activity index rises, intestinal barrier is destroyed and intestinal flora is disordered etc.;And can reduce the inflammation and oxidative damage of mouse inflammatory bowel disease.The complex probiotic of the application can be applied in the preparation of drug for treating inflammatory bowel disease;Also can be applied in the preparation of feed additive for improving the health of animal intestine, can significantly improve production efficiency and relieve intestinal injury, reduce the intestinal barrier of animal is damaged.

The application discloses a novel autoantibody combination for idiopathic retroperitoneal fibrosis and diagnostic and monitoring applications thereof. The application screens and verifies five iRPF-specific autoantibodies, including anti-RBPJ antibody, anti-TPM1 antibody, anti-C1D antibody, anti-NPM1 antibody, anti-IL-1A antibody, and IgG4 subtypes of the above antibodies; the autoantibodies are significantly increased in iRPF patients and have a medium and above ability to identify iRPF, wherein the anti-C1D antibody can effectively distinguish iRPF from RPS; and the anti-TPM1, NPM1 and RBPJ antibodies can also be used for disease activity monitoring. The screened autoantibodies directly reflect the autoimmune nature of iRPF, have higher specificity than existing laboratory indicators, can be detected by conventional laboratory equipment, have low cost and good promotion, and have good clinical application prospects.

Provided are the use of Collinsella shenzhenensis in treating and / or preventing inflammation-related diseases, cardiovascular diseases, and a composition for treating and / or preventing inflammation-related diseases, cardiovascular diseases, including a pharmaceutical product, a beverage, a food product, or an animal feed composition, etc., and a method for improving intestinal lesions of a mammal, reducing blood lipid levels of a mammal, controlling weight loss of a mammal, and / or reducing disease activity index (DAI) of a mammal.

The present invention relates to a method for predicting disease activity in patients with a chronic inflammatory disease, a method for identifying individual influencing factors on disease activity in chronic inflammatory diseases, and a method for reducing the frequency and / or intensity of disease flares in patients with a chronic inflammatory disease. The methods according to the invention enable a patient to prepare early for expected changes in disease activity and to identify influencing factors on disease activity based on their individual disease or symptom history.

The application discloses an application of a NAT10 overexpression agent in preparation of a drug for treating systemic lupus erythematosus, wherein the NAT10 overexpression agent is a lentivirus for overexpression of NAT10, the accession number of the CDS sequence of the NAT10 gene in the NCBI database is NM_024662.3, and the drug for treating systemic lupus erythematosus refers to a drug capable of reducing neutrophil iron death and reducing the disease activity of systemic lupus erythematosus; the NAT10 overexpression agent provided by the application can overexpress the NAT10 gene through cell experiments, has a significant effect on reducing the neutrophil iron death level of a systemic lupus erythematosus patient and reducing the disease activity of systemic lupus erythematosus, and has a gene therapy purpose on systemic lupus erythematosus, thereby providing a new targeted therapy drug for clinical treatment of systemic lupus erythematosus.

The present application relates to the technical field of systemic vasculitis identification, in particular to a biomarker for systemic vasculitis diagnosis and application thereof, wherein the biomarker combination comprises the following serum markers: cold-inducible RNA binding protein, myeloid cell trigger receptor-1, Toll-like receptor 4. The biomarker provided by the present application is used for systemic vasculitis diagnosis, disease activity assessment, kidney damage risk early warning and treatment effect monitoring, so as to solve the technical problem of lack of specific and sensitive biomarkers in the prior art.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of ethyl acetate extract of turmeric in the preparation of drugs for treating acute ulcerative colitis. The preparation method of the extract is as follows: turmeric slices are soaked overnight in 10-20 times their weight in a 60%-80% ethanol solution, refluxed at 80-90°C for 2-4 times, each time for 1-3 hours. The extracts are combined and concentrated until no alcohol odor remains, then dried to constant weight to obtain the total extract. The total extract is reconstituted with water and extracted 2-4 times with ethyl acetate at an equal volume ratio. The extracts are combined and dried to constant weight to obtain the final product. Experimental results show that this extract can significantly improve weight loss, disease activity index, colonic shortening, and histopathological damage in model mice, and effectively upregulate intestinal tight junction proteins and downregulate the expression of pro-inflammatory factors and pro-apoptotic proteins. This extract can be formulated into various dosage forms, providing a new natural drug option for the treatment of UC.

The application discloses application of guaiacol in preparation of a drug for treating ulcerative colitis. Cell experiment results show that the guaiacol can enhance the ability of macrophages to remove apoptotic cells; animal experiment results show that the guaiacol can significantly relieve the disease of a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse, and the specific performance is that the guaiacol can slow down the weight loss degree of the colitis mouse, effectively reduce the disease activity index (DAI) of the colitis mouse, significantly inhibit the shortening of the colon of the colitis mouse, the infiltration of inflammatory cells and the mucosal damage, obviously reduce the level of a pro-inflammatory factor in serum of the mouse, and increase the level of a pro-inflammatory repair factor. In conclusion, the guaiacol has definite curative effect on ulcerative colitis, has no obvious side effect, and has a good prospect of being developed into a drug for treating ulcerative colitis.

The application provides serum biomarkers for diagnosing and evaluating the activity of aortitis and application, and relates to the field of disease activity evaluation. The serum biomarkers are serum proteins: HP and ORM1. HP and ORM1 are determined as two new serum biomarkers through comprehensive proteomics analysis; gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis are carried out using a DAVID database; a protein-protein interaction network is constructed using Metascape. A random forest model is trained using a caret package, and a nomogram is visualized using an rms package. Serum samples are obtained, and the serum levels of HP and ORM1 are determined using a commercial ELISA kit; they are significantly related to disease activity, and are involved in inflammation / immune processes in aortitis, so the markers have the potential to serve as an auxiliary tool for monitoring the activity of aortitis.